At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 145 enrolled
Drug / intervention
Roxadustatdrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase 2, Randomized, Open-Label, Dose Titration, Efficacy and Safety Study of FG-4592 (Roxadustat) in Non-Dialysis Chronic Kidney Disease Patients With Anemia
In Brief
A Phase 2 clinical trial evaluating Roxadustat for Chronic Kidney Disease and Anemia. Completed, enrolled 145 participants across 38 sites in 2 countries.
Detailed Summary
The primary purpose of this study is to evaluate efficacy and safety of roxadustat in the correction of anemia in participants with non-dialysis chronic kidney disease.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsChronic Kidney Disease, Anemia
CountriesPuerto Rico, United States
CollaboratorsAstellas Pharma Inc
Timeline
Phase 2CompletedFinished
2011201220132014201520162017201820192020202120222023202420252026
Enrollment StartOct 2010
First PostedNov 2010
Primary CompletionJun 2012
TodayJul 2026
First PostedNov 19, 2010
Enrollment StartOct 29, 2010
Primary CompletionJun 13, 2012
TodayJul 2, 2026
Enrollment to primary: 1.6 yearsPosted 15.6 years ago
Interventions
Roxadustatdrug
Oral capsule